A
Antonio Digiandomenico
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
NOV 9
NOV 16
Nov 10, 2026
Episode 36: Optimizing monoclonal antibody therapeutics for bacterial pathogens
13:18
And I guess thinking about monoclonal antibody therapeutics, what's sort of the, I guess, the next step or like how, like obviously you're trying to make them better, make them more efficacious, you know, what are sort of the, some of the big questions of these particular types of therapeutics?
A
13:38So I think one of the biggest things for monoclonal antibodies is When you're thinking about the patient experience, you want that coverage to be as long-term as possible.
A
13:51And as you may know, antibodies, typically we usually develop human IgG1s as monoclonal antibodies because they have a lot of favorable characteristics in terms of half-life and so forth.
A
14:11And so the question that we always have is, well, how can we make this half-life longer so that you don't have to continually treat with this particular drug? And so you look at antibody half-life extension technology.
A
14:24I know we have a couple here at AstraZeneca and many other companies used to extend the half-life technology.
A
14:31We've seen with some of our other drugs that we can provide upwards of 90 to 100 days of half-life coverage.
17:52
And then I guess thinking about your field in general, so like developing these monoclonals, what are some of the challenges that your field faces right now? And I guess maybe talking a little bit about also, you know, what has AI or the ability to use AI, has that actually been beneficial for your program? Are you using it a lot? Things like that.
